Immunomic Therapeutics Overview

  • Founded
  • 2005
Founded
  • Status
  • Private
  • Employees
  • 34
Employees
  • Latest Deal Type
  • Later Stage VC
  • Latest Deal Amount
  • $77.7M
Latest Deal Amount
  • Investors
  • 18

Immunomic Therapeutics General Information

Description

Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer, allergies and animal health. The company's immunomodulation platform, LAMP-Vax, enables nucleic acid immunotherapy (DNA or RNA) to utilize the body's natural biochemistry to develop an immune response, including antibody production, cytokine release and critical immunological memory, enabling health industries to transform the rapidly growing allergy and cancer immunotherapy markets.

Contact Information

Formerly Known As
Immunomic Therapeutics Delaware
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Primary Office
  • 15010 Broschart Road
  • Suite 250
  • Rockville, MD 20850
  • United States
+1 (301) 000-0000

Immunomic Therapeutics Timeline

2019202020212022
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Immunomic Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
16. Later Stage VC 14-Jan-2021 $77.7M 00000 Completed Generating Revenue
15. Debt - PPP 03-May-2020 00000 000.00 Completed Generating Revenue
14. Secondary Transaction - Private 01-Jan-2020 000.00 Completed Generating Revenue
13. Later Stage VC 03-Aug-2018 00000 000.00 Completed Generating Revenue
12. Later Stage VC 15-May-2017 00.000 000.00 Completed Generating Revenue
11. Grant 13-May-2015 00.00 000.00 Completed Generating Revenue
10. Later Stage VC 29-Jan-2015 0000 000.00 Completed Generating Revenue
9. Later Stage VC (Series A) 24-Apr-2014 00.000 000.00 Completed Generating Revenue
8. Debt - General 16-Jul-2013 $3M $8M Completed Generating Revenue
7. Later Stage VC (Series A) 01-Sep-2012 $2.9M $5M Completed Generating Revenue
To view Immunomic Therapeutics’s complete valuation and funding history, request access »

Immunomic Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of lysosomal-associated membrane protein (LAMP)-based vaccines designed to use immunotherapy to treat cancer,
Drug Discovery
Rockville, MD
34 As of 2021
00000
0000000000 0 00000

00000

enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo conseq
0000000000000
Cambridge, MA
000 As of 0000
00000
000000&0

00000000

iam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute ir
0000 000000000
Alameda, CA
000 As of 0000
00000
000000000 00000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Immunomic Therapeutics Competitors (17)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Agios Formerly VC-backed Cambridge, MA 000 00000 000000&0
00000000 Formerly VC-backed Alameda, CA 000 00000 000000000 00000
00000 000000000 Formerly VC-backed Boulder, CO 000 00000 000000&0 00000
000000 00000000000 Corporation Plymouth Meeting, PA 000 000.00 00000000 000.00
0000000 0000000000 Formerly VC-backed Brisbane, CA 000 00000 000000&0 00000
You’re viewing 5 of 17 competitors. Get the full list »

Immunomic Therapeutics Patents

Immunomic Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-3793595-A1 Improved lamp constructs comprising allergens Pending 15-May-2018 000000000000
CA-3100004-A1 Improved lamp constructs comprising allergens Pending 15-May-2018 000000000000
JP-2021523185-A Improved lamp constructs containing allergens Pending 15-May-2018 000000000000
US-20210261647-A1 Lamp constructs comprising allergens Pending 15-May-2018 000000000000
CA-3061206-A1 Improved lamp constructs Pending 22-Apr-2017 C07K14/70596
To view Immunomic Therapeutics’s complete patent history, request access »

Immunomic Therapeutics Executive Team (12)

Name Title Board Seat Contact Info
William Hearl Ph.D Co-Founder, Chief Executive Officer, President & Board Member
Eric Winzer Chief Financial Officer & Board Member
Timothy Coleman Ph.D Senior Vice President, Operations & General Manager
Teri Heiland Ph.D Co-Founder & Chief Scientific Officer
Lawrence Weiner MD Medical Director
You’re viewing 5 of 12 executive team members. Get the full list »

Immunomic Therapeutics Board Members (16)

Name Representing Role Since
Alex Kim Self Board Member 000 0000
Arlo McGinn Ph.D Immunomic Therapeutics Board Member 000 0000
Bokhwan Chun Immunomic Therapeutics Board Member 000 0000
Bruce Mackler Ph.D Immunomic Therapeutics Board Member 000 0000
Charles Grudzinskas Ph.D Self Board Member 000 0000
You’re viewing 5 of 16 board members. Get the full list »

Immunomic Therapeutics Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Immunomic Therapeutics Investors (18)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
HLB Corporation Minority 000 0000 000000 0
National Institutes of Health Government 000 0000 000000 0
United States Department of Defense Government 000 0000 000000 0
Astellas Pharma Corporation Minority 000 0000 000000 0
Daniel Geselowitz Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 18 investors. Get the full list »

Immunomic Therapeutics Investments (3)

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
00000000 02-Feb-2017 0000000000 Biotechnology 0000 0000
00000000 02-Feb-2017 0000000000 Drug Discovery
miRecule 02-Feb-2017 Accelerator/Incubator Drug Discovery
To view Immunomic Therapeutics’s complete investments history, request access »